Compare Stocks: YMAB, ANAB, MAZE, and SEPN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$53.36 -3.1%	$57.73	$11.40 ▼ $72.36	$1.63B	0.68	757,606 shs	451,354 shs
MAZE Maze Therapeutics	$26.92 -2.6%	$27.36	$12.81 ▼ $53.65	$1.53B	2.14	448,123 shs	335,578 shs
SEPN Septerna	$34.45 -2.1%	$33.58	$10.62 ▼ $38.04	$1.59B	2.29	389,803 shs	241,094 shs
YMAB Y-mAbs Therapeutics	$8.61	$8.58	$3.55 ▼ $8.61	$391.24M	0.54	637,200 shs	N/A

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-3.05%	-1.46%	-18.45%	-20.07%	+113.61%
MAZE Maze Therapeutics	-2.57%	-2.75%	-9.69%	-1.27%	+73.68%
SEPN Septerna	-2.08%	+4.08%	-0.46%	+45.91%	+172.55%
YMAB Y-mAbs Therapeutics	0.00%	0.00%	0.00%	0.00%	+79.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$53.36 -3.1%	$57.73	$11.40 ▼ $72.36	$1.63B	0.68	757,606 shs	451,354 shs
MAZE Maze Therapeutics	$26.92 -2.6%	$27.36	$12.81 ▼ $53.65	$1.53B	2.14	448,123 shs	335,578 shs
SEPN Septerna	$34.45 -2.1%	$33.58	$10.62 ▼ $38.04	$1.59B	2.29	389,803 shs	241,094 shs
YMAB Y-mAbs Therapeutics	$8.61	$8.58	$3.55 ▼ $8.61	$391.24M	0.54	637,200 shs	N/A

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-3.05%	-1.46%	-18.45%	-20.07%	+113.61%
MAZE Maze Therapeutics	-2.57%	-2.75%	-9.69%	-1.27%	+73.68%
SEPN Septerna	-2.08%	+4.08%	-0.46%	+45.91%	+172.55%
YMAB Y-mAbs Therapeutics	0.00%	0.00%	0.00%	0.00%	+79.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.67	Moderate Buy	$82.00	53.67% Upside
MAZE Maze Therapeutics	3.00	Buy	$66.00	145.17% Upside
SEPN Septerna	2.82	Moderate Buy	$45.89	33.20% Upside
YMAB Y-mAbs Therapeutics	2.00	Hold	$8.60	-0.12% Downside

Current Analyst Ratings Breakdown

Latest YMAB, ANAB, MAZE, and SEPN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	SEPN Septerna	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/1/2026	SEPN Septerna	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$52.00 ➝ $45.00
7/1/2026	SEPN Septerna	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $43.00
7/1/2026	SEPN Septerna	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
6/24/2026	MAZE Maze Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/11/2026	SEPN Septerna	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$52.00
6/11/2026	SEPN Septerna	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/10/2026	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$95.00
6/8/2026	SEPN Septerna	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Strong-Buy	$47.00 ➝ $53.00
6/2/2026	ANAB AnaptysBio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/15/2026	ANAB AnaptysBio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$90.00

(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$234.60M	6.73	N/A	N/A	$1.34 per share	39.82
MAZE Maze Therapeutics	$167.50M	8.90	N/A	N/A	$7.38 per share	3.65
SEPN Septerna	$45.95M	33.80	N/A	N/A	$8.53 per share	4.04
YMAB Y-mAbs Therapeutics	$87.68M	4.46	N/A	N/A	$2.05 per share	4.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	-$1.08	N/A	16.42	N/A	-11.53%	N/A	-7.75%	8/5/2026 (Estimated)
MAZE Maze Therapeutics	-$131.12M	-$2.53	N/A	N/A	N/A	N/A	-36.62%	-31.78%	N/A
SEPN Septerna	-$48.88M	-$0.81	N/A	N/A	N/A	-49.88%	-12.72%	-8.87%	8/10/2026 (Estimated)
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.50	N/A	N/A	N/A	-26.03%	-24.60%	-18.89%	N/A

Latest YMAB, ANAB, MAZE, and SEPN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	SEPN Septerna	-$0.4260	N/A	N/A	N/A	$19.20 million	N/A
8/5/2026	Q2 2026	ANAB AnaptysBio	-$0.1252	N/A	N/A	N/A	$17.33 million	N/A
5/12/2026	Q1 2026	ANAB AnaptysBio	-$0.6436	-$1.84	-$1.1965	-$1.84	$18.86 million	$25.56 million
5/12/2026	Q1 2026	MAZE Maze Therapeutics	-$0.43	-$0.45	-$0.02	-$0.45	N/A	$20.00 million
5/11/2026	Q1 2026	SEPN Septerna	-$0.4167	-$0.19	+$0.2267	-$0.19	$16.98 million	$26.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
SEPN Septerna	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
MAZE Maze Therapeutics	0.11	17.88	17.88
SEPN Septerna	N/A	4.71	4.71
YMAB Y-mAbs Therapeutics	N/A	4.00	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
MAZE Maze Therapeutics	N/A
SEPN Septerna	N/A
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
MAZE Maze Therapeutics	5.30%
SEPN Septerna	5.80%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.61 million	20.28 million	Optionable
MAZE Maze Therapeutics	121	55.35 million	52.41 million	N/A
SEPN Septerna	N/A	45.08 million	42.46 million	N/A
YMAB Y-mAbs Therapeutics	150	45.44 million	36.49 million	Optionable

YMAB, ANAB, MAZE, and SEPN Headlines

Recent News About These Companies

Y-Mabs Therapeutics Completes Merger with Perseus BidCo

September 16, 2025 | tipranks.com

Y-Mabs Therapeutics’ Phase 2 Trial: A Potential Breakthrough for Neuroblastoma Treatment

September 7, 2025 | msn.com

Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?

September 1, 2025 | zacks.com

Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

August 19, 2025 | globenewswire.com

Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock

August 13, 2025 | insidermonkey.com

A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast

August 9, 2025 | benzinga.com

Y-mAbs (YMAB) Q2 Revenue Falls 14%

August 9, 2025 | aol.comA

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

August 8, 2025 | zacks.com

Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders

August 8, 2025 | businesswire.com

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

August 8, 2025 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

August 7, 2025 | prnewswire.com

Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

August 7, 2025 | businesswire.com

Y-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings Call

August 7, 2025 | quiverquant.comQ

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

August 7, 2025 | globenewswire.com

HC Wainwright & Co. Downgrades Y-mAbs Therapeutics (YMAB)

August 7, 2025 | msn.com

SERB bets on rare cancer drug in $412 million deal for Y-mAbs

August 6, 2025 | thepharmaletter.comT

Jones Trading Downgrades Y-mAbs Therapeutics (YMAB)

August 6, 2025 | msn.com

YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?

August 6, 2025 | zacks.com

Shareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

August 5, 2025 | prnewswire.com

Y-mAbs stock soars after SERB Pharmaceuticals announces acquisition

August 5, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

YMAB, ANAB, MAZE, and SEPN Company Descriptions

AnaptysBio NASDAQ:ANAB

$53.36 -1.68 (-3.05%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$53.24 -0.12 (-0.22%)

As of 07/31/2026 07:34 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Maze Therapeutics NASDAQ:MAZE

$26.92 -0.71 (-2.57%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$27.94 +1.02 (+3.79%)

As of 07/31/2026 07:58 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Septerna NASDAQ:SEPN

$34.45 -0.73 (-2.08%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$34.45 0.00 (0.00%)

As of 07/31/2026 07:34 PM Eastern

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

Y-mAbs Therapeutics NASDAQ:YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YMAB, ANAB, MAZE, and SEPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YMAB, ANAB, MAZE, and SEPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YMAB, ANAB, MAZE, and SEPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

YMAB, ANAB, MAZE, and SEPN Company Descriptions

AnaptysBio NASDAQ:ANAB

Maze Therapeutics NASDAQ:MAZE

Septerna NASDAQ:SEPN

Y-mAbs Therapeutics NASDAQ:YMAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest YMAB, ANAB, MAZE, and SEPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest YMAB, ANAB, MAZE, and SEPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

YMAB, ANAB, MAZE, and SEPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

YMAB, ANAB, MAZE, and SEPN Company Descriptions

AnaptysBio NASDAQ:ANAB

Maze Therapeutics NASDAQ:MAZE

Septerna NASDAQ:SEPN

Y-mAbs Therapeutics NASDAQ:YMAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools